Hiddo J.L. Heerspink
University Medical Center Groningen
Internal medicineUrologyEndocrinologyRenal functionRandomized controlled trialIntensive care medicineAlbuminuriaType 2 diabetesDapagliflozinKidney diseaseDiseaseDiabetic nephropathyCreatinineNephropathyMicroalbuminuriaPopulationClinical trialDiabetes mellitusMedicineBlood pressure
432Publications
70H-index
15.5kCitations
Publications 432
Newest
#1Lesley A. Inker (Tufts Medical Center)H-Index: 58
#2Hiddo J. Lambers-Heerspink (UMCG: University Medical Center Groningen)H-Index: 2
Last. Tom Greene (UofU: University of Utah)H-Index: 111
view all 17 authors...
Abstract Rationale & Objective An early change in proteinuria is considered a reasonably likely surrogate endpoint in IgA nephropathy (IgAN), and can be used as basis for accelerated approval of therapies with verification in a post-marketing confirmatory trial. GFR slope is a recently validated surrogate endpoint for CKD progression and may be considered as the endpoint used for verification. We undertook a meta-analysis of clinical trials in IgAN to compare treatment effects on change in prote...
1 CitationsSource
#1Tamara Young (The George Institute for Global Health)H-Index: 4
#2Jingwei Li (The George Institute for Global Health)H-Index: 10
Last. Vlado Perkovic (The George Institute for Global Health)H-Index: 93
view all 14 authors...
Aims/hypothesis null Type 2 diabetes mellitus can manifest over a broad clinical range, although there is no clear consensus on the categorisation of disease complexity. We assessed the effects of canagliflozin, compared with placebo, on cardiovascular and kidney outcomes in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program over a range of type 2 diabetes mellitus complexity, defined separately by baseline intensity of treatment, duration of diabetes and glycaemic control. null ...
Source
#1Brendon L. Neuen (The George Institute for Global Health)H-Index: 11
#2Megumi Oshima (Kanazawa University)H-Index: 7
Last. José Luis Górriz (University of Valencia)H-Index: 16
view all 19 authors...
Aims null Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optimal use of agents that block the renin-angiotensin-aldosterone system, particularly in patients with chronic kidney disease (CKD). In patients with CKD, sodium‒glucose cotransporter 2 (SGLT2) inhibitors provide cardiorenal protection, but whether they affect the risk of hyperkalaemia remains uncertain. null Methods and results null The CREDENCE trial randomized 4401 participants with T2DM and C...
1 CitationsSource
Source
#1Taha Sen (UG: University of Groningen)
#2Jingwei Li (The George Institute for Global Health)H-Index: 10
Last. Yshai Yavin (Janssen Pharmaceutica)H-Index: 4
view all 13 authors...
AIMS/HYPOTHESIS Higher plasma concentrations of tumour necrosis factor receptor (TNFR)-1, TNFR-2 and kidney injury molecule-1 (KIM-1) have been found to be associated with higher risk of kidney failure in individuals with type 2 diabetes in previous studies. Whether drugs can reduce these biomarkers is not well established. We measured these biomarkers in samples of the CANVAS study and examined the effect of the sodium-glucose cotransporter 2 inhibitor canagliflozin on these biomarkers and asse...
Source
#1Hiddo J.L. Heerspink (UMCG: University Medical Center Groningen)H-Index: 70
#2Austin G. Stack (UL: University of Limerick)H-Index: 22
Last. Vlado Perkovic (The George Institute for Global Health)H-Index: 93
view all 11 authors...
Background null Verinurad is a human uric acid transporter (URAT1) inhibitor known to decrease serum uric acid (sUA) levels and may reduce albuminuria. In a Phase 2a study (NCT03118739), treatment with verinurad + febuxostat lowered urine albumin-to-creatinine ratio (UACR) at 12 weeks by 39% (90% confidence interval: 4%, 62%) among patients with type 2 diabetes mellitus, hyperuricaemia and albuminuria. The Phase 2 b, randomised, placebo-controlled Study of verinurAd and alloPurinol in Patients w...
Source
#1Kamlesh Khunti (University of Leicester)H-Index: 96
#2Bernard Charbonnel (University of Nantes)H-Index: 43
Last. Discover investigatorsH-Index: 2
view all 19 authors...
We report the prevalence and change in severity of chronic kidney disease (CKD) in DISCOVER, a global, 3-year, prospective, observational study of patients with type 2 diabetes (T2D) initiating second-line glucose-lowering therapy. CKD stages were defined according to estimated glomerular filtration rate (eGFR). Overall, 7843 patients from 35 countries had a baseline serum creatinine measurement. Of these (56.7% male; mean age: 58.1 years; mean eGFR: 87.5 mL/min/1.73m2 ), baseline prevalence est...
Source
#1Annemarie B van der Aart-van der Beek (UG: University of Groningen)H-Index: 1
#2David Z.I. Cherney (UHN: University Health Network)H-Index: 45
Last. Hiddo J.L. Heerspink (AstraZeneca)H-Index: 70
view all 11 authors...
High protein intake may increase intraglomerular pressure through dilation of the afferent arteriole. SGLT-2 inhibitors may reduce intraglomerular pressure through activation of tubuloglomerular feedback. Given these opposing effects, we assessed whether the effect of dapagliflozin on glomerular filtration rate (GFR) and urinary albumin-to-creatinine ratio (UACR) was modified by estimated dietary protein intake using data from three separate randomized controlled trials (DELIGHT, IMPROVE and DIA...
Source
#1Charlotte C. van Ruiten (VUMC: Vanderbilt University Medical Center)
#1Charlotte C. van Ruiten (VUMC: Vanderbilt University Medical Center)H-Index: 1
Last. Hiddo J.L. Heerspink (UG: University of Groningen)H-Index: 70
view all 7 authors...
AIMS Sodium glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) slow progression of kidney function decline, possibly through complimentary yet distinct mechanisms of action, providing a rationale for combination therapy. However, there is limited data on the effects of the combined use of SGLT2i and GLP-1RA on parameters of kidney function. METHODS In this prespecified secondary analysis of the DECREASE trial, we enrolled 66 obese patients with t...
Source
#1Sara Sokooti (UMCG: University Medical Center Groningen)H-Index: 1
#2Jose L Flores-Guerrero (UMCG: University Medical Center Groningen)H-Index: 6
Last. Robin P. F. Dullaart (UMCG: University Medical Center Groningen)H-Index: 69
view all 6 authors...
Background null Triglyceride-rich lipoproteins particles (TRLP) and low density lipoprotein particles (LDLP) vary in size. Their association with β-cell function is not well described. We determined associations of TRLP and LDLP subfractions with β-cell function, estimated as HOMA-β, and evaluated their associations with incident T2D in the general population. null Methods null We included 4818 subjects of the Prevention of Renal and Vascular End-Stage Disease (PREVEND) study without T2D at base...
Source